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Summary Background A phase I study to assess the
maximum tolerated dose (MTD) of a short course of afatinib
in combination with docetaxel for the treatment of solid
tumors. Methods Patients with advanced solid malignancies
received docetaxel 75 mg/m2 intravenously on day 1 and oral
afatinib once daily on days 2–4, in 3-week treatment cycles.
The afatinib dose was escalated in successive cohorts of 3–6
patients until dose-limiting toxicity (DLT). The MTD cohort
was expanded to 13 patients. Pharmacokinetic parameters
were assessed. Results Forty patients were treated. Afatinib
doses were escalated to 160 mg/day in combination with
75 mg/m2 docetaxel. Three patients had drug-related DLTs
during cycle 1. The MTD was defined as 90 mg/day afatinib
(days 2–4) with docetaxel 75 mg/m2. The most frequent
drug-related adverse events (all grades) were alopecia,
diarrhea, stomatitis (all 50 %) and rash (40 %, all grade ≤2).
Three patients had confirmed responses, two patients had
unconfirmed responses and nine patients had durable stable
disease >6 cycles. No pharmacokinetic interaction was
observed. ConclusionAfatinib 90 mg administered for 3 days
after docetaxel 75 mg/m2 is the MTD for this treatment
schedule and the recommended phase II/phase III dose. This
combination showed anti-tumor activity in phase I, with a
manageable adverse-event profile.
Keywords Phase I . BIBW 2992 . Afatinib . Epidermal
growth factor receptor . Tyrosine kinase inhibitor .
Pharmacokinetics
Introduction
The epidermal growth factor receptor (EGFR/ErbB)
family—EGFR/human epidermal growth factor receptor
(HER1/ErbB1), HER2 (ErbB2), ErbB3 (HER3) and ErbB4
(HER4)—are tyrosine kinase receptors that play an integral
role in cell growth, proliferation, differentiation and migra-
tion, as well as angiogenesis through activation of complex
intracellular signalling pathways [1]. Dysregulation of
EGFR/HER2 expression has been observed in a variety of
malignancies and is associated with more aggressive disease
and poor clinical outcome [1–3].
Afatinib (BIBW 2992, Boehringer Ingelheim) is a potent
orally bioavailable, irreversible ErbB-Family Blocker.
Afatinib inhibits EGFR, with a half-maximal inhibitory
concentration (IC50) of 0.5 nM, HER2 with an IC50 of
14 nM [4] and ErbB4 with an IC50 of 1 nM [5]. It has been
proposed that irreversible binding to the target receptor, as
well as multiple inhibition of ErbB-family members, includ-
ing inhibition of trans-phosphorylation of ErbB3 [4], may
help to overcome resistance that can develop with reversible
small-molecule EGFR tyrosine kinase inhibitors (TKIs) or
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agents targeting HER2 [6]. In vivo and in vitro data suggest
that afatinib is active in the L858R/T790M double mutant,
which is resistant to reversible EGFR TKIs [4]. In the
clinical setting, afatinib has demonstrated efficacy in
patients with a range of solid tumors when administered
according to different treatment schedules [7–10].
There remains an unmet need to identify improved ther-
apeutic strategies for patients with locally advanced or
metastatic tumors. One approach is the combination of
TKIs with chemotherapy. Preclinical in vivo and in vitro
data suggest potent anti-tumor activity of afatinib in combi-
nation with docetaxel [11]. Studies have suggested that
continuous administration of TKI therapy with chemother-
apy may be inferior to the administration of either agent
alone [12–14]. Therefore, different scheduling strategies for
the combination of these agents are needed.
Previous research has suggested that pharmacodynamic
separation of EGFR TKIs and chemotherapy, specifically
administration of erlotinib after chemotherapy, may lead to
greater efficacy than seen with either agent alone [15–18]. In
the case of erlotinib administration following docetaxel, it
has been hypothesized that docetaxel induces M-phase
arrest and apoptosis, which is then enhanced by erlotinib
[15]. Preclinical findings support this dosing approach with
afatinib. Docetaxel administration followed by afatinib was
shown to inhibit tumor growth in xenograft-bearing mice
more potently than afatinib followed by docetaxel [11, 19].
This phase I, dose-finding study was conducted to assess
the maximum tolerated dose (MTD) and incidence of ad-
verse events (AEs) of docetaxel (60 or 75 mg/m2), followed
by 3 days of afatinib in a pulsatile treatment schedule.
Materials and methods
Study design and treatment
This phase I study was performed at two study centers in
Belgium between 2005 and 2008 and was conducted in-line
with the Declaration of Helsinki/International Conference
on Harmonization Good Clinical Practice Guideline. It was
approved by national regulatory and local ethics committees.
All patients provided written informed consent.
Patients received an intravenous (IV) infusion of doce-
taxel on day 1 followed by three single, orally administered
daily doses of afatinib on days 2–4 of each 3-week treatment
cycle. Afatinib was administered in the morning (1 h prior to
food intake) at a starting dose level of 10 mg and subse-
quently doubled until the occurrence of a drug-related
dose-limiting toxicity (DLT) assessed by the Common
Terminology Criteria for Adverse Events (CTCAE; version
3.0) in one or more patients. Escalation steps of a maximum
of 50 % were used thereafter, unless a DLT was observed in
one of six patients, in which case escalation steps were
limited to ≤35 %. Docetaxel was initiated at 60 mg/m2 IV
infusion and increased to 75 mg/m2 IV infusion in the
absence of DLT.
A standard ‘3+3’ design was used. The MTD was
defined as the highest dose of afatinib at which no more
than one out of six patients experienced a DLT. Once the
MTD was determined, a further 12 evaluable patients were
included at the MTD level.
A drug-related DLT was defined as any of the following
events during the first cycle: CTCAE grade 3 or 4 neutro-
penia of any duration associated with fever (>38.5 °C);
CTCAE grade 4 neutropenia (not associated with fever for
>7 days); platelets <10,000/μL or grade 3 thrombocytopenia
associated with bleeding requiring transfusion; CTCAE
grade 3/4 skin, central nervous system, cardiac, lung or
respiratory, or hepatic AEs; grade ≥2 worsening of renal
function; grade >2 diarrhea, nausea and/or vomiting for
≥7 days despite supportive care or treatment.
Study population
Eligible patients were males or females (18 years or older)
with confirmed advanced solid malignancies historically
known to overexpress EGFR or HER2 who had progressed
after, or were not amenable to, established treatments and
for whom a therapy with proven efficacy was unavailable.
Patients were required to have an Eastern Cooperative
Oncology Group (ECOG) performance score of 0 or 1, life
expectancy of at least 3 months, and to have recovered
(CTCAE grade 0 or 1) from any drug-related AEs or previous
surgery. Patients recruited at the MTD were required to have
measurable disease according to the Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.0. Patients
who had received chemo-, immune-, radio- or hormone
therapy, or treatment with an EGFR/HER2-inhibiting drug
within 4 weeks of study initiation, were excluded. Previous
treatment with taxanes was permitted.
Concomitant medications
Prior to taxane infusions, patients were premedicated with
oral dexamethasone 8 mg twice daily for 3 days, beginning
on day −1. Other concomitant treatments were permitted, as
clinically necessary.
Study assessments
Safety was evaluated by the incidence and intensity of drug-
emergent AEs (defined by CTCAE, version 3.0), physical
examination, changes in laboratory parameters (hematology,
chemistry and urine analyses), electrocardiograms and vital
signs. Objective tumor response (defined as complete [CR]
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or partial response [PR], stable disease [SD] or progressive
disease [PD]) was assessed according to RECIST version
1.0. Target lesions were evaluated by radiography, computed
tomography or magnetic resonance imaging at screening and
at the end of every other cycle.
Pharmacokinetic sampling, data analysis and statistics
For determination of the pharmacokinetic (PK) profile of
docetaxel, blood samples were collected approximately
5 min before and 1, 2, 4 and 8 h after the start of docetaxel
infusion (day 1) in cycles 1 and 2. For the determination of
the PK profiles of afatinib, blood samples were taken before
and 1, 2, 3, 4, 5, 8 and 24 h (and 48 h only in cycle 1) after
the first administration (day 2) in cycles 1 and 2. Samples
collected before and 24 h after administration of afatinib
were also used for docetaxel PK analysis. During cycles 3
and 4, samples were drawn before the first administration of
afatinib on day 2 and 24 h after the first administration of
afatinib, immediately before drug administration on day 3.
Samples were analysed using validated high-performance
liquid chromatography tandem-mass spectrometry. PK
parameters were calculated using WinNonlin® Professional
(version 5.0.1, Pharsight® Corporation, Cary, NC, USA)
and were assessed graphically and summarised by timepoint
descriptive statistics using SAS.




Forty patients received at least one dose of afatinib (treated
set). Baseline characteristics are shown in Table 1. Of note,
20 % of patients had received previous taxane therapy.
Treatment and dosing
Afatinib was studied with docetaxel 60 mg/m2 at 10 mg/day
(n03) and with docetaxel 75 mg/m2 at 10 (n03), 20 (n03),
40 (n06), 60 (n04), 90 (n013), 120 (n05) and 160 (n03)
mg/day. Overall, 92.5 % (n037) of patients received more




DLTs during the first treatment cycle are shown in Table 2.
Three patients had a DLT during the first treatment cycle.
Table 1 Patient characteristics
Characteristic Patients












Tumor type, n (%)
Gynecologic tumors 7 (17.5)
Breast 5 (12.5)
Pancreatic 6 (15)





Previous therapies, n (%)
Surgery 36 (90)
Chemotherapy 39 (98)
Of which taxane therapy 8 (20)
Radiotherapy 19 (48)
Immunotherapy 3 (8)
Hormone therapy 5 (13)
Other 4 (10)





NSCLC non-small cell lung cancer









120 75 Grade 4 febrile
neutropenia
1
120 75 Grade 3 vomiting
and diarrhea
1
160 75 Grade 4 neutropenia 1
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One patient experienced a DLT at 75 mg/m2 docetaxel and
160 mg/day afatinib—grade 4 neutropenia for 7 days that
resolved without treatment. The dose of afatinib was
reduced to 80 mg/day in cycle 2. Based on investigator
decision, the next lower dose cohort—that is, 75 mg/m2
docetaxel and 120 mg/day afatinib—was expanded. Two
of five patients experienced DLTs, i.e. grade 4 febrile neu-
tropenia (one patient) and grade 3 vomiting and diarrhea
(one patient). Both patients fully recovered following rescue
therapy, treatment interruption or dose reduction (docetaxel
60 mg/m2 and afatinib 60 mg). Thereafter, another dose
reduction to afatinib 90 mg and docetaxel 75 mg/m2 was
made. When no further DLTs occurred, afatinib 90 mg was
determined as the MTD and recommended phase II dose,
when administered once daily for 3 days following the
administration of docetaxel 75 mg/m2.
Adverse events
Thirty-eight patients (95 %) experienced at least one drug-
related AE following afatinib and docetaxel treatment. The
most frequently reported drug-related AEs were gastrointes-
tinal disorders in 31 patients (78 %) and skin and subcuta-
neous tissue disorders in 30 patients (75 %). The most
frequently reported drug-related AEs (>10 % of patients)
are shown in Table 3. The frequency of patients with drug-
related diarrhea increased with the dose of afatinib. No
grade 5 drug-related AEs occurred.
Three patients experienced drug-related AEs after
treatment cycle 1 that were considered to be significant
AEs. During the second treatment cycle, one patient
experienced a grade 4 pulmonary embolism at 60 mg/m2
docetaxel and 10 mg/day afatinib, and a second patient
experienced a grade 4 neutropenia at 75 mg/m2 docetaxel and
120 mg/day afatinib. One patient who received 75 mg/m2
docetaxel and 10 mg/day afatinib experienced a grade 3
infection during the seventh treatment cycle.
Efficacy
Thirty-four of the 40 treated patients were evaluable for
response according to RECIST. Fourteen patients (14/40;
35.0 %) with various tumor types had either an objective
response (5/40 patients [12.5 %]; confirmed in three patients
[7.5 %]) or durable (≥6 treatment cycles) SD (9/40; 22.5 %;
Table 4).
A CR was achieved in a patient with HER2-positive
breast cancer treated with docetaxel 75 mg/m2/afatinib
40 mg at the end of cycle 6. Response was maintained
through cycle 8. This patient had been previously treated
with four cycles of doxorubicin in combination with cyclo-
phosphamide. Two patients had a confirmed PR. One
female patient with esophageal cancer treated with docetaxel
75 mg/m2 and afatinib 20 mg achieved a confirmed PR at the
end of cycle 8. This patient had previously received seven
cycles of cisplatin (two cycles)/carboplatin (five cycles) and
5-fluorouracil, and 16 courses of weekly paclitaxel. A further
breast cancer patient who had previously achieved a PR to
six cycles of cyclophosphamide, doxorubicin and 5-
fluorouracil, achieved a confirmed PR on 75 mg/m2 doce-
taxel/10 mg afatinib. Two further patients (breast cancer and
thymoma) achieved PRs that were not confirmed by a sub-
sequent scan.
Of the eight patients that had received previous taxane
therapy, three showed prolonged SD (Table 4).
Pharmacokinetics
In the MTD group, disposition kinetics of afatinib between
patients in cycles 1 and 2 appeared to be comparable
(Fig. 1a). Afatinib was detectable in pre-dose plasma sam-
ples in five out of 10 MTD patients on day 2 of cycle 2 after
the washout phase of 18 days. Afatinib plasma concentra-
tions increased with increasing doses in all dose groups
(Fig. 1b). The PK parameters of afatinib at the MTD are
shown in Table 5.
The gMean plasma concentrations of docetaxel and the
shapes of the plasma concentration–time profiles were sim-
ilar on day 1 of cycles 1 and 2 in the MTD group (Fig. 2).
The PK parameters of docetaxel 75 mg/m2 in the MTD
group are presented in Table 5. The pharmacokinetics of
all patients receiving 75 mg/m2 docetaxel was in accordance
with values for patients in the MTD group (data not shown).
Table 3 Frequency of patients with drug-related AEs of grade ≥3 for
related AEs occurring in >10 % of all patients
AE CTCAE grade (n040)
n (%)
3 4 All grades
Alopecia – – 20 (50)a
Diarrhea 2 (5) – 20 (50)
Stomatitis – – 20 (50)
Rash – – 16 (40)
Anorexia 2 (5) – 11 (28)
Nausea 1 (3) – 11 (28)
Fatigue 2 (5) – 10 (25)
Mucosal inflammation – – 08 (20)
Myalgia – – 7 (18)
Vomiting 1 (3) – 7 (18)
Neutropenia 2 (5) 4 (10) 6 (15)
Arthralgia – – 5 (13)
a One patient was mistakenly reported to have grade 3 alopecia
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Fig. 1 a Individual and gMean
plasma concentration–time
profiles of afatinib;* b
Individual and gMean dose-
normalized AUC0–24 values of
afatinib.† *After multiple oral
administration of 90 mg afatinib
tablets on days 2–4 of treatment
cycles 1–4. †After single oral
administration of 10–160 mg
afatinib tablets on day 2 of
treatment cycle 1 (overall
gMean: 8.44; n038). Abbrevi-
ations: gMean 0 geometric
mean; AUC0–24 0 area under
the concentration–time curve of
the analyte in plasma over the
time interval from 0 to 24 h
Table 4 Summary of the characteristics of patients with objective response or durable SD (≥6 treatment cycles)
Docetaxel (mg/m2) Afatinib (mg/day) Age/gender Tumor type Best response Previous taxane therapy No. of cycles
60 10 41/F Cervical SD No 10
75 10 54/F Breast (HER2-negative) Confirmed PR No 7
75 20 56/M NSCLC SD Yes 12
75 20 72/F Esophagus Confirmed PR Yes 8
75 40 36/F Renal SD No 8
75 40 65/F Breast (HER2-positive) Confirmed CR No 8
75 60 52/F Ovarian SD Yes 8
75 60 49/F Breast (HER2-negative) SD Yes 8
75 60 59/M Bladder SD No 8
75 90 46/M Pancreas SD No 6
75 90 55/M Melanoma SD No 14
75 90 62/F Breast PR No 10
75 120 38/M Stomach SD No 12
75 120 64/M Thymus PR No 3
F female; M male
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Discussion
This phase I, dose-finding study was conducted to deter-
mine the MTD and safety of 3-day pulsatile, high-dose
afatinib treatment following administration of docetaxel on
day 1 of a 21-day treatment cycle, a schedule selected based
on preclinical data. Patients with advanced cancers histori-
cally known to overexpress EGFR and/or HER2 were pref-
erentially eligible as they could potentially obtain greater
clinical benefit from ErbB inhibition. Due to the advanced
stage of the disease in many of the enrolled patients, fresh,
confirmatory biopsies for EGFR and/or HER2 overexpres-
sion were not required. Results support the feasibility of this
dosing schedule in patients with advanced solid tumors.
Short-term, pulsatile administration of afatinib allowed for
daily administration of higher afatinib doses (90 mg) than
when given continuously (40 or 50 mg [9, 10, 20]). The
MTD of afatinib using this regimen was significantly higher
than that achieved in a previous trial evaluating the MTD of
continuous afatinib (administered on days 2–21) in combina-
tion with docetaxel (administered on day 1), every 21 days. In
this previous phase I study, a higher than expected incidence
of hematologic side effects was observed, limiting dose
escalation beyond 20 mg afatinib when given in combination
with docetaxel [21].
Pulsatile administration of afatinib in combination with
docetaxel was associated with manageable AEs. Diarrhea,
stomatitis and alopecia were among the most common drug-
related AEs reported, whereas neutropenia/febrile neutropenia
were the most common DLTs. Neutropenia was also reported
as a drug-related AE in 15 % of patients. Although afatinib
monotherapy has not been associated with hematologic
events [7–10, 20], neutropenia is a well-established DLT
associated with docetaxel and rates of neutropenia reported
Table 5 Comparison of PK parameters of afatinib and docetaxel for the MTD group (75 mg/m2 docetaxel and afatinib 90 mg/day) by
treatment cycle
Afatinib pharmacokinetics
Parameter Unit Treatment cycle 1 (n013) Treatment cycle 2 to 4 (n010) gMean ratio; cycle 2 to cycle 1
gMean gCV (%) gMean gCV (%) Ratio (%) 90 % CI (%)
AUC0–24 ng•h/mL 879 62.6 995 48.3 122 95.5–154.7
Cmax ng/mL 71.4 69.5 81.2 56.7 123 94.5–160.2
tmax
a h 3.00 1.00–5.00 4.03 1.00–5.00 – –
CL/F mL/min 1040 57.5 888 52.5 – –
Vz/F L 1500 70.5 1340 50.0 – –
Docetaxel pharmacokinetics
Parameter Unit Treatment cycle 1 (n013) Treatment cycle 2 (n08) gMean ratio; cycle 2 to cycle 1
gMean gCV (%) gMean gCV (%) Ratio (%) 90 % CI (%)
AUC0–∞ ng•h/mL 3160 58.1 3260 57.7 118 94.2–146.9
AUC0–24 ng•h/mL 2630 61.5 2680 59.4 – –
Cmax ng/mL 2070 63.4 2200 42.1 115 91.3–144.2
tmax
a h 1.00 0.933–1.08 1.00 0.983–1.05 – –
t1/2 h 20.9 26.0 21.1 33.7 – –
CL mL/min 712 61.0 682 65.5 – –
Vz L 1290 81.3 1250 107 – –
VSS L 488 87.6 487 83.9 –
aMedian and range
gCV geometric coefficient of variation; CI confidence interval; Cmax maximum plasma concentration; tmax time to maximum plasma concentration;
CL/F apparent clearance of the analyte in plasma following extravascular administration; Vz/F apparent volume of distribution during the terminal
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Fig. 2 gMean plasma concentration–time profiles of docetaxel after
IV administration (75 mg/m2) on day 1 of treatment cycles 1 and 2 in
the MTD group (semi-log scale). Abbreviation: TC 0 treatment cycle
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here were comparable with those reported with docetaxel
monotherapy. The observed safety profile of combined afa-
tinib and docetaxel was consistent with documented safety
observations for the individual agents [7–10, 22, 23]; no
new safety concerns were identified. As might be anticipat-
ed based on cumulative exposure, the incidence and severity
of diarrhea and skin rash with pulsatile administration of
afatinib, as reported here, is lower than reported with con-
tinuous afatinib monotherapy [24] and, specifically, no
grade 3/4 skin rash.
Pulsatile afatinib in combination with docetaxel also
demonstrated promising signs of clinical activity (objective
response or durable SD being observed in 35.0 % of patients).
Treatment was particularly effective in patients with breast
cancer and upper gastrointestinal tumors, and one patient with
HER2-positive breast cancer achieved a CR. Several patients
who achieved objective response or durable SD had also been
previously treated with taxane therapy.
Despite inherent limitations when comparing results
between studies, it is interesting to compare our findings with
those of other studies combining pulsatile TKI dosing with
chemotherapy. An objective response rate of 35 % has been
observed with docetaxel (day 1) followed by intermittent
erlotinib (days 2–16 every 3 weeks) in previously treated
advanced NSCLC [15]. The most common grade 3/4 AE
was neutropenia (60 %). High-dose erlotinib (days 1 and 2)
with carboplatin and paclitaxel (day 3) has also been shown to
have a higher response rate (34 %) compared with either
low-dose erlotinib using the same schedule (18 %) or chemo-
therapy followed by erlotinib (28 %), again in advanced
NSCLC [25]. By contrast, intermittent high-dose gefitinib
given prior to docetaxel has reported much lower objective
response rates (11 %) and high rates of neutropenia (61 %)
[26]. Thus, work still needs to be done to fully understand the
optimal dosing strategies for the co-administration of EGFR
TKIs and chemotherapy.
A secondary objective of this trial was to evaluate the effect
of docetaxel administration on the pharmacokinetics of
afatinib and vice versa. Importantly, the afatinib exposure in
the presence of docetaxel reported here appears to be compa-
rable with that observed with afatinib monotherapy [7, 10].
Furthermore, comparison of the gMean AUC and Cmax values
of docetaxel between cycle 1 and 2 revealed only marginal
differences. This is of particular importance given the com-
plex pharmacologic profile of docetaxel and the high inter-
patient variability frequently observed [27]. Moreover, the PK
parameters of docetaxel reported in cycles 1 and 2 are similar
to those reported in the literature [28]. Based on these data, it
can be concluded that afatinib had no clinically relevant drug–
drug interaction with docetaxel in the applied treatment set-
ting. This is also in-line with data from a previous study that
investigated the combination of afatinib as continuous treat-
ment together with docetaxel [21].
In conclusion, afatinib 90 mg, when administered once
daily for 3 days after administration of docetaxel 75 mg/m2,
is the recommended dose for further clinical trials. Anti-tumor
activity—that is, objective responses (12.5 %) and durable SD
(22.5 %)—and a manageable side-effect profile were
observed in this phase I study. No drug–drug interactions were
observed between afatinib and docetaxel.
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